NA
KPRX icon

NewEdge Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

NewEdge Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42 Hold
22
– – ﹤0.01% 4100
2025
Q4 		$43 Hold
22
– – ﹤0.01% 4176
2025
Q3 		$61 Hold
22
– – ﹤0.01% 4051
2025
Q2 		$63 Hold
22
– – ﹤0.01% 3920
2025
Q1 		$66 Hold
22
– – ﹤0.01% 3840
2024
Q4 		$73 Hold
22
– – ﹤0.01% 3803
2024
Q3 		$81 Hold
22
– – ﹤0.01% 3728
2024
Q2 		$92 Hold
22
– – ﹤0.01% 3691
2024
Q1 		$141 Hold
22
– – ﹤0.01% 3691
2023
Q4 		$104 Hold
22
– – ﹤0.01% 3638
2023
Q3 		$114 Hold
22
– – ﹤0.01% 3363
2023
Q2 		$129 Hold
22
– – ﹤0.01% 3411
2023
Q1 		$668 Buy
+22
New +$822 ﹤0.01% 3207

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors's KPRX Position: Q1 2026 in Review

NewEdge Advisors held its Kiora Pharmaceuticals (KPRX) position steady in Q1 2026 at 22 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #4100.

NewEdge Advisors first reported a position in KPRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $668 in Q1 2023. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • NewEdge Advisors held 22 shares of Kiora Pharmaceuticals worth $42 as of Q1 2026.
  • NewEdge Advisors left its Kiora Pharmaceuticals share count unchanged in Q1 2026.
  • Kiora Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4100 holding.
  • NewEdge Advisors first reported a position in Kiora Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • NewEdge Advisors's Kiora Pharmaceuticals position peaked at $668 in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.